Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

164
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
164
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

185
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
185
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

131
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
131
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

191
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study.

Cancers·2026
Same author

The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI.

Journal of personalized medicine·2026
Same author

Consensus statement on mesotherapy for clinical and regulatory practice.

Rheumatology international·2026
Same author

Considerations for selecting and implementing comorbidity indices when using secondary data sources: a guide for health researchers.

International journal of population data science·2025
Same author

Cross-sectional survey investigating knowledge, attitudes and reasons for use of food supplements in rheumatological diseases: the IntegraRE study protocol.

BMJ open·2025
Same author

Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jan 5, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Biosimilars vs originators: Are they the same?

Piercarlo Sarzi-Puttini1, Daniela Marotto2, Roberto Caporali3

  • 1Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy.

Autoimmunity Reviews
|October 23, 2019
PubMed
Summary

Biosimilars offer lower-cost alternatives to biological drugs for rheumatic diseases, but concerns remain regarding long-term efficacy, safety, and the impact of switching. This review evaluates their pros and cons for clinical equivalence.

Keywords:
BiosimilarsExtrapolationInterchangeabilityOriginatorsSwitching

More Related Videos

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K

Related Experiment Videos

Last Updated: Jan 5, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Health Economics

Background:

  • Biological drugs have transformed rheumatic disease treatment.
  • Patent expiries have led to the development and marketing of biosimilars.
  • Biosimilars offer lower-cost alternatives, increasing patient access to advanced therapies.

Purpose of the Study:

  • To review the advantages and disadvantages of utilizing biosimilars.
  • To assess the clinical equivalence of biosimilars compared to originator biological drugs.
  • To address concerns regarding long-term efficacy, safety, and switching implications.

Main Methods:

  • Literature review and synthesis of existing evidence on biosimilars.
  • Analysis of regulatory perspectives and scientific society recommendations.
  • Evaluation of clinical trial data and post-marketing surveillance studies.

Main Results:

  • Biosimilars demonstrate comparable efficacy and safety profiles to originator biologics.
  • Potential economic benefits include reduced healthcare costs and expanded patient access.
  • Concerns persist regarding immunogenicity, interchangeability, and the impact of multiple switches.

Conclusions:

  • Biosimilars represent a valuable therapeutic option in rheumatology, offering significant economic advantages.
  • Careful consideration of patient-specific factors and regulatory guidance is crucial for successful implementation.
  • Further research is needed to fully understand the long-term implications of biosimilar use and switching.